Here are four notes:
1. The ThawSTAR Early Adopter Program is designed to assist companies “de-risk thawing of frozen cell therapies in early stage clinical trials through to commercialization and point-of-care.”
2. DiscGenics’ therapy candidate, IDCT, is intended for degenerative disc disease patients. The company will use the ThawSTAR technology in its U.S. clinical trial of IDCT for DDD.
3. The ThawSTAR CFT2 System is an automated cell thawing system that helps limit cell handling risk and variability.
4. The ThawSTAR leverages a customized algorithm for IDCT, noting cell size, volume and cryopreservative choice. This customization will allow for the cell-based therapy’s optimal performance.
More articles on biologics:
Orthofix International updates FY 2017 earnings guidance: 5 insights
Pinnacle Spine Group files for FDA clearance of InFill Lateral Fusion System: 4 points
Dr. Abba Zubair researches whether stem cells grow faster in space: 5 highlights
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.